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Abstract 
SUGAR HIGH: FACTORS THAT INTERFERE WITH ACHIEVEMENT OF OPTIMAL 
CONTROL OF TYPE 1 DIABETES IN YOUTH. Dena J. Springer and William V. 
Tamborlane. Section of Pediatric Endocrinology, Yale-New Haven Children’s Hospital, 
New Haven, CT. 
The purpose of this study was to determine key demographic factors that interfere 
with the achievement of optimal glycemic control in youth with type 1 diabetes. The 
interplay of race and ethnicity with socioeconomic status was particularly emphasized. The 
Yale Pediatric Diabetes Clinic database was used to generate a dataset of all patients < age 
18 years and with diabetes duration > .5 years who had visits logged into the clinic database 
during the time period from January 1, 2003 to September 1, 2003. Gender, age, race and 
ethnicity, duration of diabetes, mode of insulin administration (pump vs. shots), and BMI 
were recorded from each patient’s most recent visit within the nine month time period. SES 
was extrapolated using zip codes converted into median household income based on 1999 
US Census Data. HbAlc values were determined using the Bayer 2000 method. Multiple 
linear regression analysis demonstrated that when controlling for all variables, male gender 
(p=.025), younger age (.0012), shorter diabetes duration (p=.0002), pump therapy (p<.0001), 
and higher SES (p <.01 for each $20,000 increase in income when compared with the lowest 
income category, <$40,000) were significantly associated with lower HbAlc levels, but race 
and ethnicity were not a determinant of HbAlc levels. Moreover, secondary analysis of 
individuals with median household incomes <$60,000 revealed that race and ethnicity were 
again not significant predictors of HbAlc levels, but that lower SES within the white cohort 
alone was significantly associated with higher HbAlc levels. In conclusion, low SES 
emerged as a more significant contributor to poor metabolic control in type 1 diabetes than 
race or ethnicity, which did not contribute to differences in HbAlc levels after controlling 
for SES. Furthermore, not only was pump therapy a significant factor in better metabolic 
control, but the analyses revealed the possibility of a complex relationship between pump 
therapy, SES, and race and ethnicity. 
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Introduction 
Although Banting and Best’s discovery of insulin in the early 1920’s portended a 
cure for diabetes, the benefits of tight glycemic control in diabetes were only fully 
appreciated when the results of the Diabetes Control and Complications Trial (DCCT) 
were published more than a half century later in 1993. Even though research had already 
demonstrated that the major morbidity and mortality from diabetes mellitus were related 
to micro- and macro-vascular complications and even though hyperglycemia had already 
been implicated in the pathogenesis of these complications, the DCCT was the first study 
to consistently and convincingly show the benefits of intensive therapy. What did the 
DCCT demonstrate and why did these results make the attainment of metabolic control 
and the barriers to its achievement a prime focus of diabetes research? 
In the DCCT, 1441 patients aged 13 to 39 years were randomly assigned to either 
intensive therapy or conventional therapy. Intensive therapy involved frequent blood 
glucose monitoring and the use of either continuous insulin infusion or three or more 
daily insulin injections. Conventional therapy entailed only one or two daily insulin 
injections. Participants were followed for a mean of 6.5 years during which the 
development and progression of retinopathy, nephropathy, and clinical neuropathy were 
sequentially assessed. 
The DCCT concluded that “intensive therapy effectively delays the onset and 
slows the progression of diabetic retinopathy, nephropathy, and neuropathy in patients 
with IDDM (insulin dependent diabetes mellitis).” [1] Specifically, the study found that 
intensive insulin therapy resulted in a 76% reduction in the progression of retinopathy, a 
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60% reduction in the development of clinically significant neuropathy, a 39% reduction 
in the development of microalbuminuria, and a 54% reduction in albuminuria. 
Notably, after 3 months, the intensive treatment group achieved a mean 
glycosylated hemoglobin (HbAlc), the established indicator of glycemic control, of 
approximately 7%, whereas the conventional treatment group maintained HbAlc values 
with an approximate average of 9%. This difference was statistically significant (p<.001) 
and clinically important. The study was not set up to determine a target HbAlc value, 
but secondary analyses demonstrated a continuous relationship between increasing mean 
glycosylated hemoglobin values and the rate of development of retinopathy, suggesting 
that tighter control has benefits across a spectrum of HbAlc values as illustrated in 
Figure 1. 
Figure 1. The absolute risk of sustained retinopathy progression as a function of 
the updated mean HbAlc (percentage) during follow-up in the DCCT. [1] 
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The results of the DCCT are continuing to be analyzed as the implications and 
applications of its results are explored and expanded. Many additional studies that have 
investigated population subsets and slightly different endpoints have confirmed the 
findings of the DCCT. Patients enrolled in the DCCT continued to be followed in the 
Epidemiology of Diabetes Interventions and Complications (EDIC) study. The EDIC has 
assessed whether the benefits seen in the DCCT persisted even after the randomization 
phase of the DCCT was completed. For example, the development of retinopathy and 
microalbuminuria in the DCCT adolescent cohort was studied from the end of DCCT to 
year four of the EDIC. Although the HbAlc values in both the former conventional and 
intensive treatment groups experienced a regression toward the mean such that the 
HbAlc values were actually similar during the first 4 years of EDIC (8.38% vs. 8.45%), 
“the reduction in the risk of progression of retinopathy and nephropathy that resulted 
from the previous 6.5 years of intensive therapy (in the DCCT) persisted” [2]. This was 
shown for the entire DCCT cohort as well [3]. 
These EDIC studies suggest that poor glycemic control at any time can have long 
lasting detrimental effects on development and progression of diabetes complications 
despite improved glycemic control at a later time. The implication of this study is that 
earlier tight metabolic control is clearly better. The importance of these findings is 
amplified by studies that suggest that the incidence of type 1 diabetes mellitus appears to 
be increasing. The rise in type 1 diabetes is disproportionately affecting younger 
children, which may actually indicate a shift toward earlier incidence of the disease. 
These observations translate into increased duration of diabetes at all ages, and thus, 
increased potential for diabetic complications. [4] [5] [6] [7] [8] 
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In the post-DCCT era in diabetes management, when achieving tight glycemic 
control in type 1 diabetes is a priority especially in children and adolescents and when 
damage can apparently be irreversible or at least not easily reversed, a key question is: 
why at times, do we, as clinicians, as patients, and as a society, fail to achieve this goal of 
glycemic control? Are there systemic reasons that hinder achievement of metabolic 
control in this disease? What are the factors that predict poor glycemic control in 
children and adolescents? In particular, this study seeks to address the role of race and 
ethnicity, socioeconomic status, gender, age, duration of diabetes, body mass index 
(BMI), and mode of insulin administration (pump vs. shots) on glycemic control as well 
as the interaction of these factors. The importance of this research is supported by 
numerous and often conflicting studies that have looked at demographic and psychosocial 
parameters in attempts to delineate specific populations or characteristics that contribute 
to poor metabolic control in youth with diabetes. 
Despite the established importance of research on factors that predict glycemic 
control in youth with type 1 diabetes, studies on this topic to date have failed to present a 
coherent picture as to which factors are most important. The disagreement is due in part 
to the studies investigating and controlling for many different and varying factors, using 
different methodologies, and spanning vastly different populations. It is not surprising 
then that the studies often come to different conclusions that cannot be compared because 
of differing approaches that cause the factors analyzed, e.g., race and ethnicity, to be 
isolated and taken into account in wholly different ways. 
Another reason for the lack of coherence is the changing goals in diabetes care 
with time. In particular, the DCCT was such a pivotal study that it considerably changed 
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the approach to managing type 1 diabetes, and, consequently, all studies from the pre- 
DCCT era were not targeted at optimally controlling glucose levels and therefore are of 
limited applicability in this post-DCCT era. These caveats are not meant to discourage 
further endeavors in this discipline, but rather are intended to forewarn and to provide 
motivation to bring coherence to this field of research. 
Race and Ethnicity 
Research on disparities in health care and health outcomes is often most 
concerned with racial and ethnic inequalities, which for the purpose of this study involves 
the comparison of whites, blacks, and Hispanics. One reason for the focus on these racial 
and ethnic differences can be attributed to results from task forces such as one by the 
Department of Health and Human Services in the mid 1980’s looking at black and 
minority health. The task force found that most of the significant health disparity 
between blacks and whites could be attributed to six diseases, one of which was diabetes. 
[9] More recent research has corroborated this finding. [10] For example, Karter et al. 
confirmed that ethnic minorities including Hispanics, blacks, and Asians had increased 
incidence of diabetes-related ESRD compared to whites despite uniform medical 
coverage. [11] Tull et al. found that among 1008 participants with childhood-onset 
insulin-dependent diabetes in the Diabetes Epidemiology Research International (DERI) 
Mortality Study, blacks experienced a two-fold increase in age-adjusted mortality 
compared to whites. [12] 
In addition to wide-reaching public health findings such as were published by the 
task force, studies have specifically investigated racial and ethnic disparities in pediatric 
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populations not only between whites and blacks but also between whites and Hispanics. 
This research has created a hodgepodge of interesting and at times conflicting results. 
Several studies support the existence of racial disparities pinpointed in the 
comprehensive public health data. In a prospective study by Auslander et al. involving 
42 children, children from black, lower socioeconomic status (SES), and single-parent 
families were found to be at increased risk for poorer metabolic control than the white 
cohort, and this pattern appeared to remain up to three years after diagnosis. [13] Based 
on their statistical analysis, Auslander et al. concluded that race and number of parents in 
the home were the strongest predictors of poor metabolic control. Furthermore, the data 
suggested that the relationship between HbAlc and these factors would not be fully 
explained by SES. But as the authors caution in their conclusion, due to the 
“multicolinearity” of race and number of parents in the home, it is impossible to 
determine the individual contribution of each variable to the variance in metabolic 
control. A small black and single-parent sample size as well as the pre-DCCT date of 
this study also weaken the strength of these findings. 
In another pre-DCCT study that also found racial disparities, Hanson et al. looked 
at race and sex differences in metabolic control in an adolescent population with type 1 
diabetes as well as the possible psychosocial variables that mediate any discrepancies. In 
a sample of 27 black and 27 white adolescents, black females had higher HbAlc levels 
than each of the other groups. [14] Intriguingly, the poor metabolic control was not 
associated with a lack of knowledge about type 1 diabetes, noncompliance with 
treatment, self-concept, coping patterns, family functioning, stress, social support, or 
involvement in the health-care system, which were the psychosocial variables assessed. 
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This study raises the specter of possibly other physiologic, psychosocial, genetic and 
cultural differences that might account for the difference in metabolic control between 
races as well as genders. Despite the many factors investigated in this study, these results 
should be viewed with caution due to the small sample size. Also, because SES was not 
examined independently in this study, it is unclear how this parameter may have 
influenced the results. 
Chalew et al. also identified race as a predictor of poor glycemic control. The 
first prong of their study revealed that HbAlc values were significantly higher on average 
in 71 black children versus 80 white children in New Orleans. Furthermore, the effect of 
race on HbAlc did not appear to be influenced by sex, insurance status, body mass index, 
or number of clinic visits. Even though these authors controlled for insurance status, 
which they associated with SES, they did not explicitly control for SES and thus cannot 
rule out SES as underlying the racial differences in HbAlc. [15] Auslander et al., using 
a cross-sectional study of 146 youths with diabetes composed of 95 white and 51 black 
youth, found that black youths were in poorer control of their diabetes than the white 
participants. Furthermore, these authors found that single-parent household status and 
lower levels of adherence to diabetic control partially, but not entirely, accounted for the 
higher HbAlc values. This study controlled only for number of parents in the home, 
which, like Chalew et al’s measure of insurance status, is only imperfectly related to SES. 
[16] 
In one of the more comprehensive studies of racial differences between blacks 
and whites in diabetic control in a pediatric population, Delamater et al. assessed a 
population of 102 black children and 108 white children in a cross-sectional approach. 
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The data from this study suggests that although black children and adolescents had lower 
socioeconomic status and higher insulin dose (U/kg-day) than white children and 
adolescents, black participants nonetheless had higher HbAlc values than white 
participants even after statistically adjusting for effects of insulin dose, diabetes duration, 
and socioeconomic status [17]. Despite the seemingly definitive conclusions of this 
study especially concerning the role of race on glycemic control, this study may have 
confounded ethnicity and SES because these variables were not independently varied, an 
identical problem to that confronting the data in Auslander et al.’s prospective study. 
Another weakness of this pre-DCCT era study is that participants used twice daily insulin 
injections and thus were not primed to achieve the degree of maximal control that they 
could in the post-DCCT era. Clearly, despite compelling attempts to show directly racial 
disparity in metabolic control of type 1 diabetes, inability to separate SES and race has 
been a barrier to conclusive support of this postulate. 
Much research has also indirectly suggested poorer glycemic control in black 
children. In a small study including 29 pediatric diabetic patients, Jain et al. reported that 
the 18 black subjects with type 1 diabetes had a higher rate of poorly controlled diabetes 
than the 11 diabetic white subjects. The authors first showed a significant negative 
correlation between the degree of hyperglycemia and the level of reduced glutathione in 
erythrocytes of diabetic patients. In other words, more hyperglycemia translates into 
decreased levels of reduced glutathione in red blood cells. Then, these authors 
demonstrated that erythrocytes of black diabetic youth had significantly lower levels of 
reduced glutathione than those of white diabetic cohort. Extrapolating from these 
findings, it appears that black diabetic patients had more hyperglycemia, and therefore, 
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increased HbAlc values. [18] Many more studies have shown increased diabetes 
complications in young black adults with regard to proliferative diabetic retinopathy [19], 
renal disease [20], and mortality [12], and, thus, also suggest that poor glycemic control 
exists in black youth. 
In contrast to studies that attribute disparities in metabolic control, in part, to race, 
Overstreet et al. discount this influence. They studied 58 children with diabetes who 
were stratified by ethnicity (30 white and 28 black children) and SES. Looking at the 
outcome measures of HbAlc, number of hospitalizations, and number of hypoglycemic 
events, Overstreet et al. concluded that SES and family structure, factors that co-vary 
with ethnicity, but not ethnicity, itself, may be the best predictors of metabolic control in 
children and adolescents with diabetes. [21] This finding once again emphasizes the 
confounding role of SES with respect to isolating the effect of race on metabolic control 
in type 1 diabetes. 
On the whole, the research suggests a disparity between metabolic control in 
black and white children with type 1 diabetes. Black youth appear to be at higher risk for 
complication due to worse metabolic control. But, it is unclear whether these findings 
would persist after sufficiently segregating SES from race. Many of the studies 
previously cited have had difficulty controlling for SES and when they attempt to control 
for this variable, the role of race on metabolic control is much less clear. 
Parallel research has looked at metabolic control in Hispanic youth, the fastest 
growing ethnic minority population in the United States. In a cross-sectional study with 
183 children with type 1 diabetes composed of 99 white non-Hispanics and 84 Hispanics, 
Gallegos-Macias et al. demonstrated that Hispanic youth with type 1 diabetes were in 
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poorer metabolic control than their white non-Hispanic counterparts. Yet, unlike the 
majority of research on black and white disparities in metabolic control, after taking SES 
into account, the authors concluded that lower SES in the Hispanic population might 
explain the higher HbAlc values in that population rather than its ethnicity. [22] A pre- 
DCCT study by Kostraba et al. found little evidence of ethnic differences in clinical 
characteristics of type 1 diabetes when comparing Hispanics and non-Hispanic whites. 
[23] In fact, the two populations were similar in HbAlc levels, insulin dose, HLA-DR 
antigens, islet cell antibodies, and family history of type 1 diabetes, despite Hispanics 
being more likely to have a family history of type 2 diabetes and having higher levels of 
residual beta cell function than their white counterparts. 
Very few studies have investigated both of the largest racial and ethnic minority 
populations in the United States, blacks and Hispanics, at the same time. In one study, 
Delamater et al. looked at metabolic control and hospitalization for diabetic ketoacidosis 
(DKA) in a population of 68 black, 145 Hispanic, and 44 white children and adolescents. 
Participants in this study were primarily of lower SES. These authors found that the 
black youths had higher HbAlc values than either white or Hispanic youths. These 
results must be interpreted with caution because the black youth were less likely to have 
private insurance and thus, more likely to be of lower SES. Since this study did not look 
explicitly at SES, it is unclear how much SES might have contributed to the disparities in 
HbAlc values discovered. [24] 
On the whole, the studies of black children have suggested that these children 
tend to have poorer metabolic control than white children with type 1 diabetes, although 
the role of SES in contributing to this disparity is not entirely clear because some studies 
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do not address or control for disparities in SES and other studies report conflicting 
findings. On the other hand, the research on Hispanic youth with type 1 diabetes did not 
demonstrate any disparity between these youth and their non-Hispanic white counterparts 
that was not explained by SES discrepancies. The one study that analyzed all three racial 
and ethnic groups confirmed these findings by showing equivalent metabolic control 
between whites and Hispanics and worse glycemic control in blacks when compared to 
both of the other groups. [24] Moreover, all of these studies on race and ethnicity 
demonstrate that determining the factors that contribute to racial and ethnic differences in 
metabolic control in youth with type 1 diabetes is certainly not straightforward. 
Research by Chalew et al. cautions against the overly optimistic idea that 
identification of a high risk ethnic population can be easily translated into improvement 
in metabolic control. These researchers revealed that a multidisciplinary intervention 
program in Baltimore improved HbAlc values in the white children, but not in the black 
cohort. [15] Furthermore, pre-DCCT research in a population of 749 insulin-treated 
adults by Bloomgarden et al. suggests that knowledge may be unrelated to metabolic 
control. [25] 
It is clear that after identification of high risk populations especially in racial and 
ethnic minority populations, where cultural boundaries may exist, this information needs 
to be further investigated to determine what might be the best approach to improve 
glycemic control. Research using chart reviews as well as focus groups with adults who 
have type 2 diabetes has already begun to investigate ways to improve diabetes care in 
both adult Hispanic and black populations. [26] [27] [28] [29] [30] Targeting 
appropriate patients in helpful ways is the goal in the pediatric population as well, but 
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first we need convincingly to demonstrate who should be targeted. And this area of 
research clearly warrants further study especially with respect to SES because by not 
taking SES into account, studies can only suggest relationships between race and 
ethnicity and glycemic control. 
Socioeconomic Status 
Research has indicated that people living in wealthier parts of a community tend 
to be healthier. [31] This finding is not surprising. Research has repeatedly 
demonstrated that lower socioeconomic status is associated with increased morbidity and 
decreased health-promoting behavior. [32] Money buys health insurance as well as time, 
transportation, and education, all factors that make accessing health care easier. 
Consequently, one expects SES to figure prominently into disparities in diabetes control, 
and the aforementioned research on racial and ethnic disparities in the metabolic control 
of type 1 diabetes already suggested that SES has a role in metabolic control. 
When Delamater et al. found that SES did not contribute to higher HbAlc values 
in their pre-DCCT study of racial differences in metabolic control in type 1 diabetes, the 
authors were surprised. [17] Despite the interesting racial differences they found in 
metabolic control, the authors were unwilling to totally discount SES as a factor in poor 
glycemic control, a factor that might have even contributed to the significant racial 
disparities in metabolic control. They suggested: “it may not be accurate to conclude that 
socioeconomic effects are unimportant as a determinant (or at least a correlate) of poor 
metabolic control among black youths. Studies of the effect of SES are clearly dependent 
on its measurement.” 
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In the Delamater et al. study, Hollingshead Four Factor Index of Social Position 
was used to assess SES, but various other studies of SES have used different measures 
and obtained varying results. In contradiction to the Delamater et al. study, in the 
following studies, SES has often factored prominently as a predictor of poorer metabolic 
control. Gallegos-Macias et al. found a clinically and statistically significant difference 
in metabolic control based on income in both Hispanic and non-Hispanic White ethnic 
groups. [22] Overstreet et al. found that low SES determined by the Hollingshead index 
predicted poor disease control in their study of black and white youth with type 1 
diabetes. [21] Auslander et al. concluded that lower SES, based on family report, was 
one factor that increased the risk for poor diabetes control in their pre-DCCT study. [13] 
Zgibor et al. found that lower HbAlc values were associated with specialist care and that 
people from lower SES determined by annual household income experienced barriers to 
benefiting from specialist care. In fact, the benefits of specialist care in terms of lower 
HbAlc were restricted to patients with an annual income greater than $20,000. [33] 
On the other hand, several studies have generated results that discount SES as a 
contributor to metabolic control. Brandt et al., referring to findings in one of the tomes of 
diabetes - Joslin’s Diabetes Mellitus - suggested that not only is type 1 diabetes a disease 
of white children, but that in the United States, it does not vary according to income. [34] 
Handelsman et al. studied a large cohort of 1190 children with type 1 diabetes less than 
age 15 years in Australia. Using postal-code as a determinant of SES in a country with 
universal health insurance and subsidies for diabetes supplies, these authors found no 
significant difference in HbAlc based on SES or rural vs. urban location even though 
urban centers are associated with higher SES. [35] Handelsman et al.’s findings must be 
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interpreted with caution in the current context where there is no universal insurance. In 
another study, Chalew et al. used insurance status as a proxy for SES and found that it did 
not influence HbAlc. [15] As explained earlier, insurance status is an imperfect proxy 
for SES, thus, its use limits confidence in the results of this study with regard to the 
contribution, or lack thereof, that SES has in influencing HbAlc values. 
Although there is no consensus on the role of SES in influencing metabolic 
control in youth with type 1 diabetes nor the method for assessing SES, the inconclusive 
nature of the studies on this topic and the prominent place that SES has in influencing 
other health outcomes make investigating SES essential. Furthermore, the studies on 
racial and ethnic difference in metabolic control in type 1 diabetes suggest that SES must 
also be assessed as well as controlled for due to its role as a possible contributor to any 
statistical differences. 
Gender 
Gender, like race and ethnicity, is a focus of much research on health care and 
outcomes, but does gender matter with respect to metabolic control in a pediatric 
population with type 1 diabetes? Although there is some disagreement in the literature 
about whether metabolic control of type 1 diabetes in pediatric populations is affected by 
gender, when gender differences have been found, females always fare worse. 
The minority of studies have shown no gender differences in HbAlc values. In a 
pre-DCCT study, Belmonte et al. were looking at the effect of self-monitored blood 
glucose on metabolic control in 312 pediatric patients with type 1 diabetes. As an 
incidental finding from this relatively large sample, these authors determined that there 
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were no differences in the level of HbAlc or change in HbAlc between males and 
females over the three years of the study. [36] Within a cohort of 280 adult patients with 
type 1 diabetes, Enzlin et al. found that although there are gender differences in the 
psychological adjustment to type 1 diabetes, with adult women having more depressive 
coping than men, HbAlc values did not differ between the two genders. [37] Of course, 
the applicability of this study of adults to children and adolescents is unclear. In research 
predominantly focused on racial disparities before the DCCT, Delamater et al. also found 
that in their cohort of 210 children, there were no gender difference in HbAlc nor were 
there any interactions among race, gender, and age-group. [17] In agreement with this 
finding, Chalew et al. concluded that the effect of race on HbAlc did not appear to be 
influenced by gender, insurance status, body mass index, or number of clinic visits. [15] 
Some other studies do document differences in metabolic control between males 
and females in pediatric populations. Anderson et al. in a pre-DCCT study of 58 
adolescents in either good or poor metabolic control also reported that there were gender 
differences in HbAlc values. [38] In a study investigating the effect of quality of life on 
metabolic control in 2,101 international adolescents with type 1 diabetes, Hoey et al. 
found that youth who scored worse on the Diabetes Quality of Life questionnaire had 
higher HbAlc, and in general, girls scored worse on the quality of life measure. [39] 
Bryden et al. looked at glycemic control in 76 individuals of which 43 were male and 22 
were female and who were 11 to 18 years old at the study’s inception. These authors 
found that, on average, HbAlc values were highest in late adolescence, and females had 
worse metabolic control than males. [40] Palta et al. identified female sex as a major 
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risk factor for hospitalization, primarily due to hyperglycemia, in a cohort of 577 
individuals younger than age 30 with type 1 diabetes in Wisconsin. [41] 
Some studies suggest that gender difference in metabolic control appear to endure 
through adulthood. In a study of 858 adults with type 1 diabetes in North East Wales, 
Child et al. found that HbAlc was statistically significantly higher in women compared to 
men, even when controlling for age, diabetes duration, insulin regimen, and monitoring 
method. When investigating metabolic control in insulin-dependent diabetes across the 
lifespan, Pound et al. found that glycemic control was worse in females than in males. 
[42] 
Other studies have found that when metabolic control of type 1 diabetes was 
affected by gender, HbAlc was also moderated by other variables. As cited earlier. 
Hanson et al. found in their pre-DCCT era study that in a sample of 27 black and 27 
white adolescents, black females had worse HbAlc than black males as well as white 
males and females. [14] In their study of Italian youth, Vanelli et al. found that girls 
exhibit a more prominent deterioration in glycemic control as diabetes duration increased. 
[43] In a pre-DCCT era study in Denmark, Mortensen et al. reviewed charts of visits by 
884 Danish youth with diabetes, representing 70-80% of all children and adolescents in 
the country with the disease, and found that gender differences depended on age. In the 
group of boys and girls twelve years old or younger, there were no differences in HbAlc 
levels. On the other hand, in the adolescent cohort, girls had HbAlc values that were 4% 
higher than the boys, a level that reached statistical significance. [44] A study by Zimet 
et al. also found age effects related to gender. In their small pre-DCCT study of 23 girls 
and 17 boys aged 8-19 years, the 10 older girls had poorer control than the 10 older boys. 
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[45] In a study of Swedish youth with recently diagnosed type 1 diabetes, Lemmark et 
al. suggested that older girls had significantly higher post-remission HbAlc levels than 
younger girls and all boys. [46] 
These studies indicate that when there are gender disparities in diabetes control, it 
is the females who always have the higher HbAlc. This suggests a clear and clinically 
significant finding. However, the interplay of other factors such as age in several of the 
studies, with adolescent females doing the poorest, suggests that age or other factors 
related to age such as duration of diabetes or BMI might influence gender differences in 
metabolic control. 
Age 
Unlike many other domains of research on metabolic control in youth with type 1 
diabetes, there is consensus with regard to the deterioration of metabolic control with age, 
which has been attributed to insulin resistance during puberty and adolescence. Even 
research dating from the 1980’s, when insulin therapy was not optimal, has documented 
deterioration of metabolic control when children entered puberty and adolescence. [47] 
[48] As Arniel et al. showed in a pre-DCCT study, insulin-mediated glucose metabolism 
is impaired during puberty in both diabetic and non-diabetic individuals. Because HbAlc 
values and insulin requirements were elevated in the pubertal individuals as compared to 
the pre-pubertal cohort, the authors concluded that insulin-resistance contributes greatly 
to the impaired control of diabetes during adolescence. [49] In a study that also predated 
the DCCT, Bloch et al. used a slightly different experiment, but confirmed the insulin 
resistance of puberty. [50] Furthermore, as cited earlier in the section on gender 
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differences, female adolescents seem to fare the worst. [40] [46] [44] [45] Finally, 
Hamilton et al. explored causes of the deterioration in metabolic control during 
adolescence and discovered that in addition to the physiologic explanation linking insulin 
resistance to decreased metabolic control, there are also possible psychosocial causes of 
the deterioration in glycemic control such as noncompliance and the transition to an 
autonomous lifestyle in adolescence. [51] 
Studies have focused not only on puberty effects, but also age effects in general 
on metabolic control. In a comprehensive study examining metabolic control across a 
spectrum of ages, Pound et al. looked at a total of 1,874 patients with type 1 diabetes for 
11 years. The authors found that despite improvements in glycemic control in all age 
groups during the study period from 1982 to 1993, mean HbAlc rose between the ages of 
10 and 16 years before falling and reaching a nadir at 27 years. [42] In a study of 201 
Italian youth, Vanelli et al. documented that glycemic control deteriorates with 
progression of diabetes duration, reaching the nadir of metabolic control at age 14 years 
in girls and age 16 years in boys, similar ages to that found by Pound et al. and ages that 
represent puberty and adolescence in the respective sexes. [43] Delamater et al. had 
similar results by dividing their cohort into older children, 13 years or older, and younger 
children, younger than age 13 years. The older children had higher HbAlc values. [17] 
Child et al. also found a positive correlation between HbAlc and age in the male patients 
in their pre-DCCT study. [52] 
In contrast to the vast majority of studies, a handful of studies showed no 
difference in HbAlc according to age and deserve mention. Belmonte et al., in a study of 
312 children and adolescents with type 1 diabetes, found no difference in metabolic 
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control between ages. [36] These authors attribute their results, which they admit 
contradict other studies, to their practice’s use of high insulin doses in adolescents to 
maintain reasonable control. It is unlikely that higher insulin doses alone negated the 
insulin resistance of adolescence, and more likely that because all subjects were being 
treated with only one or two injections per day in this pre-DCCT era study, no one was 
able to achieve the best possible glycemic control. Therefore, it was most likely difficult 
to find differences between groups. Although not the main emphasis of their study, 
Auslander et al. likewise did not detect any difference in HbAlc values between ages in a 
study of 42 children before the DCCT. [13] Despite these studies that concluded age 
effects on metabolic control do not exist, the majority of research agrees that age affects 
glycemic control and the peak of HbAlc levels occurs during puberty and adolescence. 
Duration of Diabetes 
The “honeymoon period” in diabetes is the time when islet cell function and 
insulin production are waning but not completely absent. As expected, during this 
period, metabolic control is easier to achieve and HbAlc levels tend to be lower on the 
whole. But what happens after the “honeymoon?” Chalew et al. found that a longer 
duration of diabetes was associated with poorer metabolic control. [15] Dahlquist et al. 
supported this position with pre-DCCT results that indicated a small, but significant, 
correlation between increasing duration and worsening glycemic control. [53] In another 
pre-DCCT era study, Child et al. also found a positive correlation between decreased 
metabolic control and increased duration of disease but only in their female patients. [52] 
While following 180 children and adolescents with type 1 diabetes, Goldstein et al. saw a 
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trend in HbAlc values with duration of treatment. HbAlc levels were high initially, fell 
around days 60-90, then began to rise before reaching a plateau after approximately 4 
years. Goldstein et al. had all participants adhere to an insulin regimen of 2 shots per 
day, structured for the pre-DCCT era, but perhaps not applicable to the post-DCCT era of 
stricter glycemic control. [54] 
Contradicting these studies, another pre-DCCT study by Ionescu-Tirgoviste et al. 
reported that the HbAlc values appeared to decrease with duration of diabetes. [55] 
Other studies have found absolutely no correlation between disease duration and 
metabolic control. For example, Daneman et al. found that beyond the first year of 
disease, HbAlc was not correlated with disease duration before the DCCT. [48] And 
indirectly, Jain et al.’s results suggested no relationship between disease duration and 
glutathione in red blood cells, an indicator of metabolic control. [18] 
When duration effects are considered in the literature, much speculation has 
emerged to explain why duration of diabetes might affect HbAlc negatively. Whether 
reduced endogenous insulin secretion, increased insulin antibody formation, or other 
more psychosocial factors such as poor compliance over time are responsible remains to 
be seen. Nonetheless, it is clear that evaluating the effect of diabetes duration on 
metabolic control is complex and must be taken into account in any study evaluating 
predictors of HbAlc. 
Mode of insulin administration: pump vs. shots 
When continuous subcutaneous insulin infusion (CSII), also known as pump 
therapy, was introduced more than 20 years ago in the late 1970’s, it was heralded as a 
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major advancement in the control of type 1 diabetes. The pump provided a way to 
simulate more closely normal pancreatic insulin action. Despite the advantages of CSII 
and despite the findings in the DCCT that stressed the importance of tight metabolic 
control, pumps were utilized relatively infrequently in youth until recently. But as soon 
as people’s fears of possible complications with pump therapy were allayed, drastic 
improvements in metabolic control were achieved. 
One key example was a study of 161 children ranging in age from 18 months to 
18 years in the Yale Pediatric Diabetes Clinic, the same clinic from which the present 
data were obtained. Ahem et al. noted a significant .6-.7% decrease in HbAlc values 
after initiating pump therapy. This improvement in glycemic control was maintained 
longterm. [56] In a study from the same center, Boland et al. found that when comparing 
25 adolescents using CSII with 50 adolescents using multiple daily insulin injections 
(MDI), decreased HbAlc levels were more readily sustained in the pump group. [57] 
In one of the first longterm pump studies in children, de Beaufort et al. compared 
15 children started on CSII therapy with 15 children started on injection regimens in the 
1980’s and followed them for 2 years. From 2 months until 2 years, the children in the 
CSII cohort had better metabolic control. [58] Willi et al. started 51 children on pump 
therapy and measured their HbAlc levels at pump initiation and during the first year of 
pump use. These authors found that, on average, HbAlc values dropped significantly 
within 3 months of pump initiation and remained decreased at 12 months. Interestingly, 
this study found that HbAlc values improved the most in younger children and 
adolescents as compared to preadolescents. Futhermore, neither SES, gender, BMI, 

initial HbAlc, frequency of hypoglycemia, nor number of education visits before CSII 
predicted which HbAlc values would improve the most. [59] 
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Sulli et al. conducted a similar pump trial for 6 months in 40 patients aged 4-25 
years with type 1 diabetes. After six months, HbAlc was significantly decreased. [60] 
In a chart review of 95 pediatric patients with type 1 diabetes at John Hopkins Hospital, 
Plotnick et al. found that after controlling for diabetes duration and age, HbAlc values 
were significantly reduced after starting pump therapy compared with before initiating 
pump therapy. [61] Linkeschova et al. designed a similar experiment in which 100 adult 
patients with Type 1 diabetes were followed for 1 year prior to CSII initiation and until 
study closeout with an average follow-up period of 1.8 years. The data from this study 
indicated a significant decrease in HbAlc values. [62] In a cohort of 58 patients who 
switched from insulin injection therapy to CSII and were followed for at least one year 
prior to and following the switch, Bell et al. also found significantly decreased HbAlc 
values after pump initiation. [63] 
Several investigators set up cross-over designs to compare metabolic control 
when using pump therapy versus intensive insulin injections. DeVries et al. followed 79 
patients for 16 weeks and found that the individuals assigned to CSII had significantly 
lower HbAlc values. Due to significant drop-out, DeVries et al. could not complete the 
second part of their cross-over design. [64] Hanaire-Broutin et al. designed a similar 
study and were able to complete the crossover design. Hanaire-Broutin et al. used this 
open-label randomized crossover design to compare CSII and MDI using lispro insulin in 
41 adult patients with type 1 diabetes. The individual treatment periods were each 4 
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months long. Once again, HbAlc was lower when the participants were on pump 
therapy. [65] 
Weintrob et al. also used a randomized open crossover trial but with results that 
contradict the previous trials with similar designs. Twenty three children were enrolled 
and 3.5 months of CSII were compared to 3.5 months of MDI. These authors found no 
difference in metabolic control between CSII and MDI. [66] Of note, the short duration 
of crossover designs raises a question about whether the metabolic control achieved by 
MDI is sustainable over longer period of time or whether as time progresses, the 
metabolic control achieved by patients using MDI would fall behind CSII users. In other 
words, there is evidence to suggest that fulfilling the goals of intensive MDI for the 
longterm may not be as attainable as CSII. 
The achievement of lower HbAlc values by CSII use was once perceived to be a 
double edged sword. One of the biggest concerns with pump therapy and intensive 
control of diabetes was the risk for hypoglycemic events. This worry was based on the 
DCCT finding that intensive treatment of type 1 diabetes in this trial resulted in a two-to- 
threefold increase in severe hypoglycemia. In the DCCT, this risk of hypoglycemia was 
inversely related to decreasing glycosylated hemoglobin values primarily when using 
MDI. 
Paradoxically, tighter metabolic control using CSII has not generated similar 
frequencies of hypoglycemic events. The physiologic nature of the pump has, in fact, 
allowed better glycemic control than achieved in the DCCT with fewer hypoglycemic 
events. For example, Ahem et al. found a significant decrease in the frequency of severe 
hypoglycemic events defined as seizures or coma despite lower HbAlc values. [56] 
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Boland et al. also found fewer severe hypoglycemic events in the 25 adolescents on pump 
therapy from the same clinic. [57] Willi et al. and Sulli et al. likewise found that weight 
and hypoglycemic episodes were not adversely affected by pump initiation. [59] [60] 
Fewer hypoglycemic events after pump initiation were noted by Plotnick et al. and 
Linkeschova et al. as well. [61] [62] 
Despite this evidence, no difference in frequency of hypoglycemic events 
between CSII and MDI was found in two studies, both of which utilized crossover 
designs. [65] [66] Although Hanaire-Broutin et al. found no difference in frequency of 
hypoglycemic events between the two types of insulin administration, the authors 
operationalized hypoglycemic events differently than in other studies. These authors 
considered blood glucose levels lower than 60 mg/dL as a hypoglycemic event, whereas 
most other studies used subjective measures. And in contrast to the other studies of pump 
therapy, DeVries et al. found that the number of mild hypoglycemic events was 
significantly elevated in the pump group. [64] Like the previous study, DeVries et al. 
also used blood glucose monitoring (<3.9 mmol/L) to define hypoglycemia rather than 
subjective measures. Furthermore, the increase in number of hypoglycemic events may 
be due to the rather large and rapid improvement in HbAlc values for individuals on 
pump therapy in the DeVries et al. study. 
BMI 
Concern about body mass index (BMI) as an indicator of obesity is most often 
associated with type 2 diabetes. When BMI is studied with regard to type 1 diabetes, the 
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focus is usually on increases in BMI with tight metabolic control. Several studies have 
instead focused on the relationship between BMI and achieving glycemic control. 
Tylleskar et al. found that a person’s prepuberty BMI seems to be a risk factor for 
poor metabolic control later in adolescence and that this relationship is most pronounced 
in adolescent girls. [67] BMI was found to be inversely related to insulin sensitivity in a 
pre-DCCT study by Bloch et al. [50] Because decreased insulin sensitivity results in 
poorer metabolic control, this study suggests that increasing BMI is associated with 
worsening glycemic control. 
Although the majority of these studies looked at BMI, the preferred measure is 
BMI z-scores (BMIZ), which control for age and gender, two significant influences on 
BMI. Without controlling for age and gender, four separate relationships cannot be 
separated: the relationship between BMI values and metabolic control, the well-known 
positive correlation between age and HbAlc, the relationship between gender and 
HbAlc, and the finding that females on average have higher BMI values than males. For 
all of these reasons, it is essential to utilize BMI z-scores. 
Furthermore, although the limited research on the relationship between BMI and 
metabolic control in type 1 diabetes suggests that higher BMI correlates with poorer 
glycemic control, there is a diagnostic dilemma that precludes accepting this conclusion. 
There is an increasing burden of type 2 diabetes as well as other types of diabetes 
associated with obesity developing in youth. Often times, and especially until recently, 
these individuals with non-type 1 diabetes were grouped with type 1 diabetics. This 
mislabeling would make any study cohort with these individuals have higher insulin 
resistance, and therefore their diabetes would be more difficult to control. Because of 
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this diagnostic uncertainty, because of the potential of increased insulin resistance with 
increased BMI, and because of the suggested association between worse metabolic 
control and increased BMI in studies, it is best to control for BMI in studies looking at 
predictors of metabolic control. 
HbAlc: the outcome measure 
There are three requirements of the outcome measure, HbAlc, such that 
appropriate conclusions and applications can be made from this study. First, the outcome 
measure must correlate with metabolic control. HbAlc values have been shown to have 
a direct correlation with glycemic control even in ethnic minorities and therefore satisfy 
the first requirement. [22] Second, there must be a relationship between HbAlc values 
and a clinical outcome. Indeed, the DCCT research group determined that HbAlc could 
serve as a surrogate marker for risk of retinopathy progression. [68] Finally, non¬ 
diabetic HbAlc values should be independent of demographic variables. In the one 
comprehensive study that addressed this question, Saaddine et al. used data from the 
Third National Health and Nutrition Examination Survey from 1988 to 1994, 
encompassing 7,968 individuals aged 5 to 24 years who had not been treated for diabetes. 
This study demonstrated that there are, in fact, small differences in HbAlc values among 
subgroups. In particular, mean HbAlc values were higher in non-Hispanic blacks and 
Hispanics compared to non-Hispanic whites. As anticipated, the insulin resistance of the 
pubertal years translated into higher HbAlc levels in the 10 to 14 year old age range. 
The study also found significant gender differences with males on average having lower 
HbAlc values than females. Nonetheless, the authors concluded that despite these 
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differences across subgroups, these results “may not support the need for separate 
norms.” [69] HbAlc has been accepted in clinical and research medicine as the chief 
marker of glycemic control over the previous 6 to 8 weeks, and important HbAlc target 
values include <8.0, the goal HbAlc level in most pediatric diabetic populations based on 
the average of intensive treatment in the DCCT, and <7.0, the American Diabetes 
Association (ADA) criteria. 
Statement of purpose and hypotheses 
The primary goal of this study is to determine key demographic factors that 
predict poor glycemic control in children and adolescents with type 1 diabetes. This 
work will eventually be used as a stepping stone to provide groups at high risk for poor 
metabolic control with targeted therapy. Based on the extensive and at times conflicting 
literature on this topic, the key hypotheses involve race and ethnicity and SES. First, 
children and adolescents from the minority racial and ethnic groups are expected to have 
worse metabolic control than the white cohort. Furthermore, this hypothesis is directly 
tied to assumptions about the role of SES. Lower SES should contribute to poorer 
glycemic control, but SES should not entirely explain the racial or ethnic disparities. In 
other words, both SES and race and ethnicity should independently contribute to higher 
HbAlc values. 
The minor analyses in this study should indicate that HbAlc values increase with 
age and duration of diabetes, peaking during puberty and adolescence. Females should 
have worse metabolic control than their male counterparts. And patients on pump 
therapy should be in better glycemic control than individuals on insulin injection 
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regimens. Finally, in pure type 1 diabetic patients, there should be no relationship 
between metabolic control and BMI Z-scores. 
Methods 
Data collection 
Since 1995, the Yale Pediatric Diabetes Clinic has been collecting clinical 
outcome data using a standard case report on all patients in the program at each 
outpatient visit. The Yale Human Investigations Committee approved collection of these 
clinical data with a waiver of the requirement for written or oral consent. Data of interest 
in this study are: HbAlc, gender, age, race and ethnicity, SES, duration of diabetes, mode 
of insulin administration (pump vs. shots), and BMI. These data points were collected 
from the last visit by each patient as recorded in the database during the nine month 
period between January 1, 2003 and September 1, 2003. 
Age, gender, race and ethnicity, and mode of insulin administration were gathered 
directly from the database. HbAlc values were measured by the Bayer 2000 method and 
only the last HbAlc value for each patient from the time period sampled was included. 
Duration of diabetes was calculated as the time between the date of diagnosis and the 
most recent clinic visit during the study period. BMI was calculated from the weight and 
height recorded for the same visit and BMI z-scores were calculated per CDC 2000 data. 
Median household income was determined by correlating patient zip codes with data 
from the 1999 U.S. Census Bureau. Median household income has been used in many 
clinical settings as a surrogate for SES. [70] [71] [72] [73] [74] [75] 
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Selection Criteria 
All patients with primary type 1 diabetes who had a visit logged in the database 
between January 1, 2003 and September 1, 2003 were preliminarily included in the study, 
totaling 667 patients. One hundred and thirty clinic patients were eliminated because 
they were older than age 18 years. In the remaining dataset, 62 patients did not meet the 
duration criteria of at least .5 years to avoid any bias due to the “honeymoon period.” An 
additional seven patients were excluded from the analysis because their race was 
identified as either Asian or other and thus did not fit into the three racial and ethnic 
groups being investigated: white, black, and Hispanic. This left 468 patients. From this 
subset, patients were eliminated if they had missing data in any of the fields. Thus, five 
individuals were eliminated for lack of duration data and eight for missing income. This 
left 455 sets of data, with only 2.9% of patients eliminated for missing data. 
Statistical Analysis 
The data was analyzed using SAS software with the help of Dr. James Dziura, 
biostatistician for the Yale General Clinical Research Center. A test for departure from 
linear trend was done on all the continuous variables to determine if they were better 
modeled as continuous or categorical variables. This test indicated that duration, age, and 
BMIZ could be analyzed as continuous variables, whereas income was best analyzed as a 
categorical variable in the multiple linear regressions with the income strata in $20,000 
increments. The 5 categories used to stratify income were <$40,000, $40,000 - 60,000, 
$60,000 - 80,000, $80,000 - 100,000, and >$100,000. 
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Analysis of variance (ANOVA) was conducted on each individual variable with 
respect to HbAlc. ANOVA and Chi square tests were used to analyze any significant 
relationships among all of the variables. Additionally, multiple linear regression was 
performed on the data. Unless otherwise specified, data in the text are presented as mean 
± standard deviation and p-values <0.05 were considered statistically significant. 
Results 
Clinical Characteristics 
A total of 455 children and adolescents ranging in age from 2 to 18 years old, who 
had visits at the Yale Pediatric Diabetes Clinic between January 1, 2003, and September 
1, 2003, were included in this cross-sectional study. Table 1 illustrates the clinical 
characteristics of the study population. The mean (± SD) age and diabetes duration for 
the study population were 11.8 (± 3.9) years and 4.9 (±3.1) years. Forty-seven percent of 
the study population was female, 81.8% were white, 8.3% were black, and 9.9% were 
Hispanic. Thus, 18.2% were from a minority racial or ethnic group. Average income of 
the entire cohort was $69,959 (±31,516). Pump therapy was utilized by 63% of the 
population. The mean BMI z-score was .96 (±.90). 
Additionally, Table 1 illustrates the differences in clinical characteristics among 
the different race and ethnic groups. There were statistically significant differences 
between both minority groups and the white cohort with respect to diabetes duration 
(p=.012 for black vs. white and p=.0055 for Hispanic vs. white), SES (p<.0001 for both 
black and Hispanic vs. white), pump utilization (p<0001 for x2), and HbAlc values 
(p=.0020 for Black vs. white and p = .0002 for Hispanic vs. white). 
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Table 1: Clinical characteristics of the study population overall as well as by racial or 
ethnic group. (M ± SD) 
All White Black Hispanic 
N (%) 455 (100) 372 (81.8) 38(8.3) 45 (9.9) 
Age (years) 11.8 ± 3.9 11.9 ± .3.9 11.2 ± 3.7 11.7 ± 4.0 
Duration (years)1 4.9 ± 3.1 5.1 ±3.9 3.8 ±3.1 3.8 ±3.4 
BMIZ .96 ± .90 .93 ± .96 1.17 ± .92 1.09 ± .87 
Income2 $69,959±31,516 $76,206±28,661 $42,105±28,658 $41,811±28,657 
% Female 46.6 45.7 47.4 46.7 
% Pump3 62.9 71.8 21.1 24.4 
HbAlc (%)4 7.6 ± 1.4 7.4 ± 1.2 8.2 ± 1.6 8.2 ± 1.8 
! p=.012 (black vs. white), p=.0055 (Hispanic vs. white) 
2 pc.OOOl (for both black and Hispanic vs. white) 
3p<0001 for x2 
4 p=.0020 (black vs. white), p = .0002 (Hispanic vs. white) 
Bivariate Relationships with HbAlc 
As shown in Figure 2, HbAlc levels were significantly lower in whites than in 
either minority race or ethnic group (white: 7.4 ± 1.2, black: 8.2 ± 1.6, Hispanic: 8.2 ± 
1.8, p= .0020 for black vs. white, p = .0002 for Hispanic vs. white), in the two highest 
income categories than in the two lowest income groups (p < .01 when comparing each 
category with income >$60,000 vs. both categories with income <$60,000 as well as 
between income <$40,000 and income $40,000-60,000), in males than in females (7.4 ± 
1.6 vs. 7.7 ± 1.5, p = .018), and in pump-treated than in injection-treated (7.3 ±1.7 vs. 8.1 
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± 1.3, p <.0001). The difference in mean HbAlc levels between the two minority groups 
was not significant and the differences in mean HbAlc among the three highest income 
categories (>$60,000) were not significant. As shown in Table 2, correlation coefficients 
performed on the continuous variables demonstrated small but significant correlations 
between higher HbAlc and older age (r = .266, p<.0001) and longer diabetes duration (r 
= .194, p<.0001). Thus, the only variable that did not have a preliminary significant 
relationship with HbAlc was BMIZ. 
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Figure 2. Differences in HbAlc by race and ethnicity, income, gender, and mode of 
insulin administration. ** p< .01 vs. whites, # p < .01 vs. all lower income categories, ## 
p < .01 vs. all lower income categories, ++ p = .018 vs. males, and & p < .0001 vs. pump 
treatment. 
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Table 2: Pearson 
BMIZ. 
Correlation Coefficients Between HbAlc and Age, Duration, and 
r ILz: 
Age .266 <.0001 
Duration .194 <.0001 
BMIZ .024 .616 
Bivariate Relationships Among the Other Variables 
Parametric (ANOVA), nonparametric (x2), and correlation analyses revealed 
several significant relationships between all of the other variables. The two genders were 
well balanced across all variables aside from HbAlc; males and females were not 
significantly different with regard to age, race and ethnicity, mode of insulin 
administration, income, or BMIZ. Gender effects only approached statistical significance 
in diabetes duration with males having slightly shorter disease duration than females (4.6 
± 3.1 vs. 5.1 ± 3.1, p=.083). As mentioned earlier and also displayed in Table 1, the three 
racial and ethnic groups were significantly different with respect to SES (white $76,206 ± 
28,661, black $42,105 ± 28,658, Hispanic 41,811 ± 28,657, p<.0001 for both black and 
Hispanic vs. white), duration (white 5.1 ±3.1, black 3.8 ± 3.1, Hispanic 3.8 ± 3.1, p = 
.012 for black vs. white and p = .006 for Hispanic vs. white), and mode of insulin 
administration (x2 p< .0001). Mode of insulin administration was also significantly 
related to SES, age, and diabetes duration. Pump patients tended to have higher incomes 
($75,989 ± 30,556 vs. $59,755 ± 30,556, p<.0001), be younger (11.4 ± 3.9 vs. 12.4 ± 3.9, 
p=.0073), and have longer diabetes duration (5.2 ±3.1 vs. 4.2 ±3.1, p=.0006) than 
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patients on injection therapy. As expected, age was significantly correlated with diabetes 
duration such that longer diabetes duration correlated with older age (r =.914, p<.0001). 
Finally, lower SES was significantly correlated with higher BMIZ (r = -.095, p =.042). 
The relationships among these variables are summarized in Table 3. 
Table 3. Significant relationships among variables in the bivariate, ANOVA, and 
correlation analyses, (p-values) 
Gender Race/Ethnicity SES Mode Age Duration BMIZ 
Gender xxxx 
Race/Ethnicity NS xxxx 
SES NS <.oooi§0 xxxx 
Mode NS <.0001 <.0001 xxxx 
Age NS NS NS .0073 xxxx 
Duration 
* 
NS ,012§ NS .0006 <.0001 xxxx 
.006° 
BMIZ NS NS .042 NS NS NS xxxx 
NS not significant 
* relationship approached significance 
§ blacks vs. whites 
0 Hispanics vs. whites 
To determine more exactly the interplay of racial and ethnic groups with SES, 
whites, blacks, and Hispanics were divided into income categories. As illustrated in 
Table 4 and as expected based on the bivariate analysis that showed income disparity 
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among the racial and ethnic groups, blacks and Hispanics were severely underrepresented 
in the higher income categories. 
Table 4: Race and Ethnicity by Income 
<$40,000 $40 - 60,000 $60 - 80,000 $80- 100,000 >$100,000 
N (%) 57(12.5) 127 (27.9) 133 (29.2) 71 (15.6) 67(14.7) 
White 14(3.8) 100 (26.9) 124 (33.3) 69(18.6) 65 (17.5) 
Black 17(44.7) 14(36.8) 6(15.8) 1 (2.6) 0(0) 
Hispanic 26 (57.8) 13 (28.9) 3 (6.7) 1 (2.2) 2 (4.4) 
Due to the unequal distribution o f racial and ethnic groups across income strata, 
the roles of SES as well as race and ethnicity were further isolated by comparing HbAlc 
values across all income categories in the white cohort alone and HbAlc values across all 
racial and ethnic groups in only the two lowest income categories (<$60,000). These 
relationships are depicted in Figure 3. In the white cohort, similar to the entire 
population, there were HbAlc disparities based on income. Each of the three highest 
income categories had significantly lower HbAlc values than both of the two lowest 
income categories (p<.05), but there were no significant differences between the two 
lowest income groups or among the three highest income groups based on unadjusted 
bivariate analyses. There were also no significant differences in HbAlc values among 
race and ethnic groups in the two lowest income strata. 
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<$40 $40-60 $60-80 $80-100 >$100 
Income Category in $1,000 
Figure 3. HbAlc by income category segregated by race and ethnicity. 
* p = .03 vs. $60-80, p = .005 vs. $80-100, p = .006 vs. >$100 
x p = .048 vs. $60-80, p = .002 vs. $80-100, p = .003 vs. >$100 
Multiple Linear Regressions 
As expected and as displayed in Table 5, multiple linear regressions on all the 
variables demonstrated that male gender (p = .025), younger age (p = .0012), shorter 
diabetes duration (p = .0002), and pump treatment (p <.0001) were significantly 
associated with lower HbAlc values. On the other hand, BMIZ was not significantly 
related to HbAlc level in the multiple linear regressions. 
Table 5. Estimates and p-values for gender, age, diabetes duration, and mode of insulin 
administration in the multiple linear regression controlling for all variables. 
Estimate P = 
Male gender -.25 .025 
Age .053 .0012 
Duration .078 .0002 
Pump treatment -.62 <.0001 
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It was also important to determine whether SES or race and ethnicity were more 
determinative of better glycemic control, and thus, we ran three multiple linear 
regressions of HbAlc including either income, race and ethnicity, or both income and 
race and ethnicity. These analyses showed that race and ethnicity were significantly 
related to HbAlc only in the regression when SES was not controlled for (p = .012 for 
blacks vs. whites and p = .0031 for Hispanics vs. whites). When SES was controlled for, 
race and ethnicity were not significant. On the other hand, SES remained significant 
whether or not the model controlled for race and ethnicity or even minority status in 
general. Moreover, as shown in Table 6, the estimate and statistical significance tended 
to increase with each higher income strata except for the highest income group 
(>$100,000) which had no difference between it and the second highest income category 
($80,000- 100,000). 
As done earlier in bivariate analyses and displayed in Figure 3, we once again 
isolated the role of SES as well as race and ethnicity by performing multiple linear 
regressions on HbAlc levels across all income categories in the white cohort alone and 
HbAlc values across all racial and ethnic groups in the two lowest income categories 
(<$60,000). These regressions demonstrated that race and ethnicity did not significantly 
influence HbAlc in the two lowest income groups, but SES clearly had an effect on 
HbAlc in the white cohort: the higher the income above $60,000, the lower the HbAlc as 
shown in Table 6. 

38 
Table 6. Multiple linear regressions comparing HbAlc by income in entire study 
population and in white cohort alone. 
HbAlc by income HbAlc by income in 
white only 
Estimate* P = Estimate* P = 
Income: $40-60,000 -.54 .0056 -.50 .12 
Income: $60-80,000 -.89 <0001 -.73 .020 
Income: $80-100,000 -1.10 <.0001 -.96 .0035 
Income: >$100,000 -1.07 <.0001 -.96 .0034 
* Adjusted for gender, age, mode of insulin administration, duration of diabetes, and 
BMIZ. 
Discussion 
This study indicates that SES and not race or ethnicity per se is pivotal in 
influencing metabolic control in children and adolescents with type 1 diabetes. The 
wealthier subjects had lower HbAlc values and this effect was more pronounced as 
median household income increased up to $80,000, at which point, higher income did not 
generate any further gain. This result makes sense in the context of the literature on this 
topic that suggested that once SES was controlled for, race and ethnicity did not have the 
same influence on HbAlc values. 
Likewise, this study corroborates some established findings in the literature on 
metabolic control in type 1 diabetes: males have lower HbAlc values than females, older 
age correlates with worse metabolic control, longer duration equates with higher HbAlc 
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levels, and pump therapy corresponds with better metabolic control than injection 
therapy. 
This study differs from other research because of the large proportion of pump 
patients as well as the disparities in distribution of pumps across the different clinic 
subpopulations. For example, minority groups had less pump utilization than the white 
cohort. When the pump variable was removed from the multiple linear regression in the 
two lowest income groups (<$60,000), there was a trend toward significant differences 
between blacks and whites and between Hispanics and whites. This result suggests that 
any difference between HbAlc levels among racial and ethnic groups, at least at the Yale 
Pediatric Diabetes Clinic, might, in fact, be attributed to minority patients being less 
likely to utilize pumps. 
This finding raises questions about why this disparity in pump use may occur. Is 
the difference due to patient or provider selection? The goal of the Yale Pediatric 
Diabetes Clinic is to offer and encourage CSII as an alternative treatment to parents and 
patients if they are monitoring blood glucose >3-4 times per day, are motivated to 
achieve treatment goals, and are not easily regulated on two daily injections. Are the 
minority groups less adherent to these parameters or do they decline pumps due to 
cultural preference? Since SES was higher in pump users, does the lower SES of the 
minority groups make it harder for these individuals to adhere to strict treatment 
guidelines necessary to be a candidate for CSII or does lower SES make providers more 
wary of entrusting the complexity of pump treatment to these patients? Evidently, there 
are many unexpected and unanswered questions generated by this study that deserve 
further investigation. 
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Although this study postulates new and interesting findings related to the 
intersection of race and ethnicity, SES, and pump use in pediatric type 1 diabetes, there 
are several limitations of this study. The first limitation is related to sample selection. 
Despite the large sample size in this study, the percentages of blacks and Hispanics are 
low. The low numbers of these two minority groups makes analysis within these groups 
difficult as seen especially when stratifying the racial and ethnic groups into income 
categories. The under-representation of the minority groups in the higher income strata 
made controlling for race and ethnicity across incomes difficult. Future studies would 
benefit by establishing more equal numbers of each racial and ethnic group as well as 
more equal distribution of race and ethnicity across income strata. 
Another limitation concerns method selection. Although zip codes are often used 
as a proxy for SES, this is perhaps not the most ideal method to evaluate and segregate 
SES. A study by Deonandan et al. comparing various methods of assessing SES 
suggested that SES characteristics based on zip code were only moderately correlated 
with SES determined by methods specific to individuals such as the Hollingshead index. 
The authors concluded: “The use of census data via the postal code methods may 
therefore still be a viable method of SES estimation for internal comparisons only, but 
not necessarily for comparisons with larger reference populations, whose greater 
variability makes traditional approaches more appropriate.” [76] 
The final limitation of this study involves factor selection. Previous studies have 
illustrated the importance of controlling for variables likely to be predictors of metabolic 
control in a pediatric type 1 diabetic population. Factors that were not addressed in this 
paper that have been shown to influence glycemic control and thus deserve inclusion in 
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future studies are insulin dose/kg/day, frequency of mild and severe hypoglycemic 
events, family structure, and adherence to diabetic regimen, including carbohydrate 
counting, recording insulin doses and blood glucose values in a log book, and the number 
of times an individual monitors blood glucose per day. [77] [78] For example, Gallegos- 
Macias found that the Hispanic youth in their study tended to be less adherent to blood 
glucose monitoring than the white non-Hispanic youth. [22] The significance of this 
finding and others like it need to be appreciated in future research. 
The DCCT placed an urgency on achieving metabolic control especially in youth 
with type 1 diabetes and there has been a commensurate increase in clinical activity and 
research to address this objective. The current study has demonstrated that SES appears 
to be a more significant contributor to poor metabolic control and actually trumps racial 
and ethnic differences. Furthermore, this study suggests that not only does pump therapy 
play a significant role in tighter metabolic control, but there is perhaps a complex 
relationship between pump therapy, SES, and race and ethnicity that deserves further 
investigation. 
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